There are nearly 20 neglected tropical diseases that afflict countless people in poor countries across the globe, but developing useful treatments can be an uphill battle when the pharmaceutical industry often emphasizes medicines that are designed to generate large profits. So Mark Sullivan, a former clinical researcher at Gilead Sciences (GILD) and GlaxoSmithKline (GSK), formed a not-for-profit company called Medicines Development for Global Health in his native Australia. With financial backing from a socially minded investment fund and the cooperation of the World Health Organization, he is about to launch a treatment for river blindness that was recently approved by the FDA. The attempt marks a new model for tackling such diseases and, possibly, for other ailments, too. We spoke with him about the effort. This is an edited version of our conversation.

Pharmalot: So you worked in big pharma for many years. What did you do and what prompted you to go down this path?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy